Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 50 of 797

TitleReference numberPublishedLast updated
Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancerTA1017
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosisTA1018
Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and overTA1019
Elafibranor for previously treated primary biliary cholangitisTA1016
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancerTA1014
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTA1015
Avapritinib for treating advanced systemic mastocytosisTA1012
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuriaTA1010
Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemiaTA1013
Belzutifan for treating tumours associated with von Hippel-Lindau diseaseTA1011
Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertensionTA1009
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatmentsTA1008
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancerTA1007
Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)TA1006
Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and overTA1002
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and overTA1003
Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusionTA1004
Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangementTA1005
Iptacopan for treating paroxysmal nocturnal haemoglobinuriaTA1000
Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatmentTA1001
Vibegron for treating symptoms of overactive bladder syndromeTA999
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinomaTA997
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancerTA737
Risankizumab for treating moderately to severely active ulcerative colitisTA998
Relugolix for treating hormone-sensitive prostate cancerTA995
Linzagolix for treating moderate to severe symptoms of uterine fibroidsTA996
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal)TA994
Abaloparatide for treating osteoporosis after menopauseTA991
Burosumab for treating X-linked hypophosphataemia in adultsTA993
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapyTA992
Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosisTA988
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia BTA989
Tenecteplase for treating acute ischaemic strokeTA990
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and overTA986
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal)TA987
Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinomaTA985
Selective internal radiation therapies for treating hepatocellular carcinomaTA688
Tafamidis for treating transthyretin amyloidosis with cardiomyopathyTA984
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)TA982
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinomaTA983
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutationTA979
Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal)TA980
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA976
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and overTA977
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal)TA978
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)TA972
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosisTA127
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosisTA312
Cladribine for treating relapsing–remitting multiple sclerosisTA616
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusionTA283

Results per page

  1. 10
  2. 25
  3. 50
  4. All